Patents by Inventor John Knopf

John Knopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Variants derived from ActRIIB and uses therefor
    Patent number: 8343933
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: January 1, 2013
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • GDF3 antibodies and related methods
    Patent number: 8293238
    Abstract: The application describes compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The application also provides methods of screening compounds that modulate activity of GDF3. These compositions and methods are also useful in treating diseases associated with abnormal activity of GDF3.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: October 23, 2012
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • BMP10 antibodies and related methods
    Patent number: 8287868
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Grant
    Filed: December 9, 2008
    Date of Patent: October 16, 2012
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, John Knopf
  • Actriib-Fc polynucleotides, polypeptides, and compositions
    Patent number: 8252900
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: August 28, 2012
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • BMP10 ANTIBODIES AND RELATED METHODS
    Publication number: 20120213782
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Application
    Filed: April 9, 2012
    Publication date: August 23, 2012
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf
  • GDF3 ANTIBODIES AND RELATED METHODS
    Publication number: 20120202739
    Abstract: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.
    Type: Application
    Filed: April 23, 2012
    Publication date: August 9, 2012
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR
    Publication number: 20120183540
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 19, 2012
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • METHODS FOR INCREASING THERMOGENIC ADIPOCYTES
    Publication number: 20120148588
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 14, 2012
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • METHOD OF PROMOTING BONE GROWTH BY AN ANTI-ACTIVIN ANTIBODY
    Publication number: 20120128668
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: January 24, 2012
    Publication date: May 24, 2012
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Methods for increasing thermogenic adipocytes
    Patent number: 8178488
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: May 15, 2012
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Activin-ActRIIa antagonists and uses for treating multiple myeloma
    Patent number: 8173601
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: May 8, 2012
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Pharmaceutical preparations comprising an ALK1-Fc fusion protein
    Patent number: 8158584
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: April 17, 2012
    Assignees: Acceleron Pharma, Inc., Ludwig Institute for Cancer Research Ltd.
    Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Robert S. Pearsall, Jasbir Seehra, Kristian Pietras
  • METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS
    Publication number: 20120058115
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: July 5, 2011
    Publication date: March 8, 2012
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Method of promoting bone growth by an anti-activin B antibody
    Patent number: 8128933
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: March 6, 2012
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Method for promoting bone growth using activin-ActRIIa antagonists
    Patent number: 8067360
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: November 29, 2011
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • IL-13 BINDING AGENTS
    Publication number: 20110262435
    Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
    Type: Application
    Filed: May 2, 2011
    Publication date: October 27, 2011
    Applicant: Wyeth LLC
    Inventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
  • ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION
    Publication number: 20110218147
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Application
    Filed: May 19, 2011
    Publication date: September 8, 2011
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • Cerberus/coco derivatives and uses thereof
    Patent number: 7981857
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: July 19, 2011
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE
    Publication number: 20110171218
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Application
    Filed: December 2, 2010
    Publication date: July 14, 2011
    Applicant: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar
  • Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
    Patent number: 7960343
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: June 14, 2011
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman